对早产风险孕妇重复产前皮质类固醇的影响:个体参与者数据荟萃分析
该个体参与者数据荟萃分析纳入11项试验、4857名孕妇和5915名婴儿,评估对已有早产风险且7天前已接受初始单疗程皮质类固醇的孕妇重复给药的效果。结果显示重复给药使婴儿需要呼吸支持的风险降低(RR 0.91),但出生体重z评分较低,严重结局、儿童死亡或神经感觉残疾、产妇败血症无显著差异。作者建议重复疗程数限制在最多3个、总剂量24-48 mg。
要点
- 重复产前皮质类固醇降低婴儿呼吸支持使用(RR 0.91,95%CI 0.85-0.97),NNT为21。
- 重复给药组出生体重z评分较低(均差-0.12,95%CI -0.18至-0.06)。
- 严重结局、儿童死亡或神经感觉残疾、产妇败血症无统计学显著差异。
核心结论
- 对持续早产风险的孕妇在初始疗程后重复给予产前皮质类固醇可降低婴儿出生后需要呼吸支持的可能性并带来新生儿获益。
- 暴露于重复产前皮质类固醇的婴儿出生时体格测量值较低。
- 作者认为为获得临床获益且对生长影响最小,重复治疗疗程数应限制在最多3个,总剂量24 mg至48 mg。
研究设计与样本
- 个体参与者数据荟萃分析,纳入11项随机试验,试验于2002年至2010年间开展,分别来自美国5项、加拿大2项、澳大利亚和新西兰、芬兰、印度、英国各1项。
- 共纳入4857名孕妇和5915名婴儿,试验入组时平均孕周在27.4周至30.2周之间。
- 纳入标准为随机分配已接受初始单疗程产前皮质类固醇7天或以上、仍被认为有早产风险的孕妇,比较皮质类固醇与安慰剂或无安慰剂。
- 检索采用Cochrane妊娠和分娩检索策略,最后检索日期为2015年1月20日,偏倚风险采用Cochrane协作网标准评估,数据分析采用一阶段法。
主要发现
- 婴儿严重结局比例无显著差异(相对风险RR 0.92,95%置信区间CI 0.82至1.04,5893名婴儿,11项试验,异质性p=0.33)。
- 暴露于重复产前皮质类固醇的婴儿呼吸支持使用减少(RR 0.91,95%CI 0.85至0.97,5791名婴儿,10项试验,异质性p=0.64),预防一名婴儿需要呼吸支持的需治疗人数NNT为21名妇女/胎儿(95%CI 14至41)。
- 重复皮质类固醇组出生体重z评分较低(均差-0.12,95%CI -0.18至-0.06,5902名婴儿,11项试验,异质性p=0.80)。
- 儿童死亡或任何神经感觉残疾以及产妇败血症等主要结局均未观察到统计学显著差异。
- 暴露于2-5个重复疗程的婴儿与仅暴露于单个重复疗程的婴儿相比,严重结局和呼吸支持使用均减少;但重复疗程数增加与出生体重、身长和头围z评分更大程度降低相关。
关键数值与推荐
- 重复产前皮质类固醇与呼吸支持使用减少相关:RR 0.91(95%CI 0.85至0.97)。
- 重复产前皮质类固醇与出生体重z评分较低相关:均差-0.12(95%CI -0.18至-0.06)。
- 作者建议重复治疗疗程数限制在最多3个,总剂量24 mg至48 mg。
临床怎么用
- 对持续早产风险且7天前已接受初始单疗程产前皮质类固醇的孕妇,重复给药可减少婴儿呼吸支持需求。
- 作者建议为获得临床获益且对生长影响最小,重复疗程数限制在最多3个,总剂量24 mg至48 mg。
局限性
- 并非所有试验都能提供所有预设亚组的数据,限制了检测差异的效能,因为某些重要的产妇、婴儿和儿童结局事件率较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infants born preterm compared with infants born at term are at an increased risk of dying and of serious morbidities in early life, and those who survive have higher rates of neurological impairments. It remains unclear whether exposure to repeat courses of prenatal corticosteroids can reduce these risks. This individual participant data (IPD) meta-analysis (MA) assessed whether repeat prenatal corticosteroid treatment given to women at ongoing risk of preterm birth in order to benefit their infants is modified by participant or treatment factors. METHODS AND FINDINGS: Trials were eligible for inclusion if they randomised women considered at risk of preterm birth who had already received an initial, single course of prenatal corticosteroid seven or more days previously and in which corticosteroids were compared with either placebo or no placebo. The primary outcomes for the infants were serious outcome, use of respiratory support, and birth weight z-scores; for the children, they were death or any neurosensory disability; and for the women, maternal sepsis. Studies were identified using the Cochrane Pregnancy and Childbirth search strategy. Date of last search was 20 January 2015. IPD were sought from investigators with eligible trials. Risk of bias was assessed using criteria from the Cochrane Collaboration. IPD were analysed using a one-stage approach. Eleven trials, conducted between 2002 and 2010, were identified as eligible, with five trials being from the United States, two from Canada, and one each from Australia and New Zealand, Finland, India, and the United Kingdom. All 11 trials were included, with 4,857 women and 5,915 infants contributing data. The mean gestational age at trial entry for the trials was between 27.4 weeks and 30.2 weeks. There was no significant difference in the proportion of infants with a serious outcome (relative risk [RR] 0.92, 95% confidence interval [CI] 0.82 to 1.04, 5,893 infants, 11 trials, p = 0.33 for heterogeneity). There was a reduction in the use of respiratory support in infants exposed to repeat prenatal corticosteroids compared with infants not exposed (RR 0.91, 95% CI 0.85 to 0.97, 5,791 infants, 10 trials, p = 0.64 for heterogeneity). The number needed to treat (NNT) to benefit was 21 (95% CI 14 to 41) women/fetus to prevent one infant from needing respiratory support. Birth weight z-scores were lower in the repeat corticosteroid group (mean difference -0.12, 95%CI -0.18 to -0.06, 5,902 infants, 11 trials, p = 0.80 for heterogeneity). No statistically significant differences were seen for any of the primary outcomes for the child (death or any neurosensory disability) or for the woman (maternal sepsis). The treatment effect varied little by reason the woman was considered to be at risk of preterm birth, the number of fetuses in utero, the gestational age when first trial treatment course was given, or the time prior to birth that the last dose was given. Infants exposed to between 2-5 courses of repeat corticosteroids showed a reduction in both serious outcome and the use of respiratory support compared with infants exposed to only a single repeat course. However, increasing numbers of repeat courses of corticosteroids were associated with larger reductions in birth z-scores for weight, length, and head circumference. Not all trials could provide data for all of the prespecified subgroups, so this limited the power to detect differences because event rates are low for some important maternal, infant, and childhood outcomes. CONCLUSIONS: In this study, we found that repeat prenatal corticosteroids given to women at ongoing risk of preterm birth after an initial course reduced the likelihood of their infant needing respiratory support after birth and led to neonatal benefits. Body size measures at birth were lower in infants exposed to repeat prenatal corticosteroids. Our findings suggest that to provide clinical benefit with the least effect on growth, the number of repeat treatment courses should be limited to a maximum of three and the total dose to between 24 mg and 48 mg.
引用
- Crowther CA, Middleton PF, Voysey M, et al. Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis. PLoS Med. 2019. PMID: 30978205. doi:10.1371/journal.pmed.1002771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。